
Mandate of the Risk and Compliance Committee

Approved by the Board of Directors on April 30, 2024

TABLE OF CONTENTS

1.	RESPONSIBILITY	1
2.	MEMBERS	1
3.	CHAIR	1
4.	TENURE	1
5.	QUORUM, REMOVAL AND VACANCIES	1
6.	DUTIES	2
7.	REPORTING	4
8.	FREQUENCY OF MEETINGS AND <i>IN CAMERA</i> SESSIONS	4
9.	RETENTION OF EXPERTS	4
10.	REVIEW AND DISCLOSURE	4

LOBLAW COMPANIES LIMITED
(the “Company”)

Mandate of the Risk and Compliance Committee

1. RESPONSIBILITY

The Risk and Compliance Committee (the “Committee”) is responsible for assisting the Board of Directors of the Company (“Board”) in fulfilling its oversight responsibilities in relation to:

- i. the Company’s enterprise risk management program;
- i. the Company’s legal and regulatory compliance and ethics program;
- ii. the Company’s policies, management systems and performance with respect to environmental matters, occupational health and safety, wellness, and pharmacy/ pharmaceutical matters;
- iii. the Company’s policies and compliance with food safety and product safety matters, including safe preparation and handling standards;
- iv. the Company’s environmental, social and governance (ESG) initiatives, including those with respect to corporate social responsibility matters, responsible and ethical sourcing, and human rights matters; and
- v. such other duties as may be delegated to the Committee by the Board.

2. MEMBERS

The Board shall appoint a minimum of three (3) directors to be members of the Committee. No more than one member of the Committee shall be a management director.

3. CHAIR

Each year, the Board shall appoint one member from amongst the non-management directors to be Chair of the Committee. If, in any year, the Board does not appoint a Chair, the incumbent Chair shall continue in office until a successor is appointed. The Board has adopted and approved a position description for the Chair which sets out their role and responsibilities.

4. TENURE

Each member shall hold office until their term as a member of the Committee expires or is terminated, or a successor is duly appointed.

5. QUORUM, REMOVAL AND VACANCIES

A majority of the Committee’s members shall constitute a quorum. Any member may be removed and replaced at any time by the Board. The Board may fill vacancies in the Committee by appointment from among the members of the Board. If a vacancy exists on the Committee, the remaining members shall exercise all powers so long as a quorum remains in office.

6. DUTIES

The Committee shall have the duties set out below as well as any other duties that are specifically delegated to the Committee by the Board:

(a) Oversight of Legal and Regulatory Compliance & Ethics Program

The Committee shall be responsible for overseeing the Company's legal and regulatory compliance program and the ethics program. The Committee shall monitor the Company's legal and regulatory compliance and ethics programs and shall receive quarterly reporting from the Executive Vice President and Chief Legal Officer, the Vice President, Compliance and Ethics, as the head of the compliance and ethics function, and from the compliance function leads in the Company's business. The Committee shall bring material information and developments relating to compliance and ethics to the attention of the Board. The Committee shall review on an annual basis the performance of the compliance and ethics programs and the Vice President, Compliance and Ethics.

Specifically, in overseeing the Company's compliance and ethics functions, the Committee shall, by way of example:

- i. review and approve the compliance and ethics mandate annually;
- ii. review the actions taken by management in order for management to ensure that the Company has high quality systems for implementing the Company's policies with respect to legal and regulatory compliance and ethical conduct, including the Company's Supplier Code of Conduct and Human Rights Statement, such systems to involve appropriate standards, education, supervision and inspection;
- iii. review the actions taken by management in order for management to ensure that colleagues are: (a) aware of the Company's policies with respect to legal and regulatory compliance and ethical conduct, and (b) expected to deal with legal and regulatory compliance, and ethics, issues expeditiously or to bring such issues to the attention of the most appropriate management personnel;
- iv. review the actions taken by management in order for management to ensure that the Company provides the following as appropriate to franchised businesses, recognizing their arm's length status: (a) standards and programs with respect to legal and regulatory compliance and ethical conduct, and (b) timely and effective support and education with respect to legal and regulatory compliance matters and ethical conduct matters;
- v. receive and review periodic reports from management and such independent consultants, if any, as the Committee shall consider appropriate, on legal and regulatory compliance matters, such reports to note in particular any significant government requests for action and the manner of dealing with the same. The Committee shall also receive and review periodic reports from management on the Company's whistleblower hotline, ethics program, loss prevention/asset protection and claims management matters; and
- vi. receive and review periodic reports from management on current and emerging issues and proposed legislation in respect of applicable legal and regulatory compliance matters as they may affect the Company's operations and shall bring to the attention of the Board such issues as it shall think appropriate.

(b) Food Safety

The Committee shall review the actions taken by management in order for management to ensure that food safety programs address safe manufacturing, handling and preparation standards, that suppliers of food products adhere to high safety standards, and that best

practices are in place for storage, handling, distribution and packaging of food product, along with the necessary control systems to monitor compliance with such policies.

(c) Pharmacy Related Matters

The Committee shall oversee any risks related to the production, handling and dispensing of pharmaceuticals and the operation of pharmacies and shall monitor and assess the Company's effectiveness in managing such risks. The Committee shall satisfy itself that management has taken appropriate actions to ensure that such risks are managed in accordance with best practices. The Committee shall receive periodic reports from management in order to perform its oversight role.

(d) Enterprise Risk Management

Except to the extent that responsibility is reserved by the Board for overarching governance of the Company's risk portfolio, the Committee shall review the design and structure of the Company's enterprise risk management program and shall monitor and assess its effectiveness. On an annual basis, the Committee shall review and recommend to the Board for approval the Company's enterprise risk management policy, risk appetite statement, and annual plan. The Committee shall oversee those principal risks delegated to it by the Board and shall satisfy itself that management has taken appropriate actions to ensure the effective management of such risks. The Committee shall receive periodic reports from management responsible for enterprise risk in order to perform its oversight role. The Chair of the Committee shall periodically report to the Board on its responsibilities with respect to ensuring that risk management oversight is carried out across the Board's Committees.

(e) Information Technology Systems and Information Technology

The Committee shall review management's oversight of matters relating to information technology affecting the Company and the Company's information technology systems. The Committee shall receive regular reports from the Company's Chief Technology & Analytics Officer with respect to the Company's systems, policies, controls and procedures that management has implemented to identify, manage and mitigate risks related to information technology and the Company's information technology systems, including cyber-security.

(f) Environmental, Social and Governance ("ESG")

Except to the extent that responsibility is reserved by the Board for overarching governance of the Company's ESG matters, the Committee shall oversee the Company's ESG strategy, design and program and shall monitor and assess the Company's progress against its ESG related goals. The Committee shall receive and review periodic reports from management on elements of the Company's ESG initiatives, including those with respect to corporate social responsibility. The Committee shall review and recommend to the Board for approval the Company's annual ESG Report.

(g) Incident Reporting

- i. The Committee shall bring to the attention of the Board any serious problems or deviations that management cannot deal with expeditiously or within reasonable economic bounds, and shall submit to the Board periodic reports as to the Committee's activities;
- ii. the Committee shall receive timely reports on any serious incidents, including any involving a breach or violation of the Company's policies. The Committee will ensure that the proper action is taken by management to promptly rectify the situation and to

proactively minimize any risks of such incident occurring at other locations or facilities;
and

- iii. the Committee shall undertake such additional activities within the scope of its responsibilities as it shall deem appropriate in its discretion to ensure best practices with respect to the reporting of such incidents are followed.

7. REPORTING

The Committee shall report to the Board on:

- i. the Company's legal and regulatory compliance and ethics program, the performance of the Vice President, Compliance and Ethics and the performance of each of the other compliance function leads in the Company's business;
- ii. the Company's performance of its obligations and objectives relating to legal and regulatory compliance and ethics matters, including in respect of environmental matters, food safety and food production, occupational health and safety, wellness, and pharmacy/ pharmaceutical matters;
- iii. the adequacy of the Company's internal control and monitoring systems with respect to legal and regulatory compliance and ethics matters, including in respect of environmental matters, food safety and food production, occupational health and safety, wellness, and pharmacy/pharmaceutical matters;
- iv. the enterprise risk management program for which oversight has been delegated by the Board to the Committee; and
- v. all other material matters dealt with by the Committee.

8. FREQUENCY OF MEETINGS AND IN CAMERA SESSIONS

The Committee shall meet at least quarterly at the call of the Chair. Meetings may also be called by any member of the Committee or by the Secretary of the Committee. Following each regularly-scheduled meeting of the Committee, the Committee members shall meet *in camera*.

9. RETENTION OF EXPERTS

The Committee may engage such special legal, accounting or other experts, without Board approval and at the expense of the Company, as it considers necessary to perform its duties.

10. REVIEW AND DISCLOSURE

This Mandate shall be reviewed by the Committee at least annually and be recommended to the Board for approval with such amendments as the Committee proposes.

This mandate shall be posted on the Company's website.